» Articles » PMID: 8314017

Multiple Low-dose Streptozocin-induced Diabetes in NOD-scid/scid Mice in the Absence of Functional Lymphocytes

Overview
Journal Diabetes
Specialty Endocrinology
Date 1994 Mar 1
PMID 8314017
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The murine severe combined immunodeficiency (scid) mutation was used to assess whether the diabetogenic effects of multiple low-dose streptozocin (MD-STZ) administration required the presence of functional T-cells. An STZ dose as low as 30 mg/kg body wt for 5 days induced hyperglycemia in young NOD/Lt-+/+ male mice, whereas a dose of 50 mg/kg for 5 days was required to elicit comparable hyperglycemia in C.B.-17-+/+ male mice. The greater NOD strain sensitivity was not a function of preexisting insulitis, because insulitis- and diabetes-free NOD male mice congenic for a diabetes-resistant major histocompatibility complex haplotype were equally susceptible to MD-STZ. This was confirmed in NOD-scid/scid and C.B.-17-scid/scid males. Both were completely insulitis-free, and despite the absence of functional T- cells and B-cells, both congenic stocks were as sensitive to MD-STZ as congenic +/+ controls. Indeed, MD-STZ-induced hyperglycemia in NOD-scid/scid male mice was significantly higher than in NOD/Lt-+/+ male mice. The NOD-scid/scid mouse as a recipient of adoptively transferred splenocytes clearly delineated a distinct pathogenesis of spontaneous insulin-dependent diabetes mellitus (IDDM) versus MD-STZ-induced hyperglycemia. Splenocytes from spontaneously diabetic NOD/Lt males, but not those from donors given MD-STZ, readily transferred IDDM, even when host beta-cells were sensitized by a single injection of STZ before adoptive transfer. We conclude that IDDM induced by MD-STZ is not mediated by T-cell- or B-cell-dependent autoimmune mechanisms in a fashion analogous to the spontaneous IDDM characteristic of NOD mice.

Citing Articles

Nε-(1-Carboxymethyl)-L-lysine, an advanced glycation end product, exerts malignancy on chondrosarcoma via the activation of cancer stemness.

Chang T, Lan K, Wu C, Sheu M, Yang R, Liu S Arch Toxicol. 2023; 97(8):2231-2244.

PMID: 37314482 DOI: 10.1007/s00204-023-03539-8.


Particle-Based therapies for antigen specific treatment of type 1 diabetes.

Lukesh N, Middleton D, Bachelder E, Ainslie K Int J Pharm. 2022; 631:122500.

PMID: 36529362 PMC: 9841461. DOI: 10.1016/j.ijpharm.2022.122500.


DPSC Products Accelerate Wound Healing in Diabetic Mice through Induction of SMAD Molecules.

Greene C, Anderson S, Barthels D, Howlader M, Kanji S, Sarkar J Cells. 2022; 11(15).

PMID: 35954256 PMC: 9368341. DOI: 10.3390/cells11152409.


Pathogenic Mechanism of Autoimmune Diabetes Mellitus in Humans: Potential Role of Streptozotocin-Induced Selective Autoimmunity against Human Islet -Cells.

Zhu B Cells. 2022; 11(3).

PMID: 35159301 PMC: 8834428. DOI: 10.3390/cells11030492.


Syntaxin 4 Mediates NF-κB Signaling and Chemokine Ligand Expression via Specific Interaction With IκBβ.

Veluthakal R, Oh E, Ahn M, Bhowmick D, Thurmond D Diabetes. 2021; 70(4):889-902.

PMID: 33526588 PMC: 7980198. DOI: 10.2337/db20-0868.